Novartis’ Cosentyx achieves primary and secondary endpoints in psoriatic arthritis study

This article was originally published here

Cosentyx is claimed to be the first and only fully-human biologic, which directly restricts interleukin-17A (IL-17A), a cornerstone cytokine engaged in the inflammation and development of PsA, psoriasis

The post Novartis’ Cosentyx achieves primary and secondary endpoints in psoriatic arthritis study appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply